

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD3

RRID:AB_396863

Type: Antibody

Proper Citation

BD Biosciences Cat# 557757, RRID:AB_396863

Antibody Information

URL: http://antibodyregistry.org/AB_396863

Proper Citation: BD Biosciences Cat# 557757, RRID:AB_396863

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD3

Description: This monoclonal targets CD3

Target Organism: baboon, cynomolgus, rhesus

Antibody ID: AB_396863

Vendor: BD Biosciences

Catalog Number: 557757

Record Creation Time: 20250820T013736+0000

Record Last Update: 20250820T112553+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Lebrec H, et al. (2025) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. *iScience*, 28(5), 112447.

Liu XF, et al. (2025) Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma. *Cell reports. Medicine*, 6(5), 102096.

Karaliota S, et al. (2025) Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques. *iScience*, 28(4), 112232.

Short D, et al. (2025) Protocol for isolating cervico-vaginal fluid cells from *Macaca mulatta* to study immunological and functional changes during pregnancy. *STAR protocols*, 6(3), 103927.

Madden PJ, et al. (2025) Diverse priming outcomes under conditions of very rare precursor B cells. *Immunity*, 58(4), 997.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. *Cell reports. Medicine*, 6(2), 101967.

Ma KM, et al. (2025) HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. *Science immunology*, 10(110), eadt6660.

Antonini Cencicchio M, et al. (2025) Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity. *Cell reports. Medicine*, 6(4), 102028.

Huang Y, et al. (2025) CD9 antibody enhances the anti-leukemia efficacy of ??T cells in adult B cell acute lymphoblastic leukemia. *iScience*, 28(11), 113752.

Bu W, et al. (2024) Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells. *Immunity*, 57(3), 559.

Saunders KO, et al. (2024) Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques. *Cell*, 187(1), 79.

Zhou P, et al. (2023) Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. *Immunity*, 56(3), 669.

Perrett HR, et al. (2023) Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. *Cell reports*, 42(5), 112524.

Darrah PA, et al. (2023) Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. *Cell host & microbe*, 31(6), 962.

Hora B, et al. (2023) Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies. *Cell reports*, 42(3), 112255.

Yu J, et al. (2023) Ad26.COVS and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. *Cell reports. Medicine*, 4(4), 101018.

Ols S, et al. (2023) Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. *Immunity*, 56(10), 2425.

Banerjee K, et al. (2023) VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. *Cell reports*, 42(12), 113507.

Ishii H, et al. (2022) Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8⁺ T cell responses. *Cell reports. Medicine*, 3(2), 100520.

Nogimori T, et al. (2022) Functional changes in cytotoxic CD8⁺ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. *Frontiers in immunology*, 13, 1081047.